Teva Pharmaceutical Industries Ltd Welcomes The Uk Medicines & Healthcare Regulatory Agency (Mhra) Decision To Grant A Licence For Ongavia, A Biosimilar To Lucentis (Ranibizumab), An Eye Injection. The United Kingdom Is The First Country In Europe To Authorize Commercialization Of Ongavia For The Treatment Of Neovascular (Wet) Age-Related Macular Degeneration (Amd).Ongavia Is Also Licenced For: The Treatment Of Visual Impairment Due To Diabetic Macular Oedema (Dme); The Treatment Of Proliferative Diabetic Retinopathy (Pdr); The Treatment Of Visual Impairment Due To Macular Oedema Secondary To Retinal Vein Occlusion (Branch Rvo Or Central Rvo); And The Treatment Of Visual Impairment Due To Choroidal Neovascularisation (Cnv).Ranibizumab Inhibits Vascular Endothelial Growth Factor (Vegf), Which Is Responsible For The Excessive Formation Of Blood Vessels In The Retina. Teva'S Biosimilar Ranibizumab Is Highly Similar To Its Reference Medicine In Terms Of Clinical Efficacy, Ocular And Systemic Safety In The Treatment Of Patients With Amd And Its Other Indications, As Shown In The Columbus-Amd Study (A Randomized, Double-Masked, Parallel Group, Multi-Centre Phase Iii Study).Welcoming The News, Richard Daniell, Executive Vice President, Teva Europe Commercial, Said:
Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.
Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.
Start using market intelligence today and allow yourself to be in control in the API market.
Check it out today and make more informed sourcing decisions! Learn More!